

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 2, 2026

SANGAMO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation)

000-30171
(Commission
File Number)

68-0359556
(IRS Employer
ID Number)

501 Canal Blvd., Richmond, California 94804
(Address of principal executive offices) (Zip Code)

(510) 970-6000
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value per share	SGMO	Nasdaq Capital Market*

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

*Following a determination by the Nasdaq Stock Market LLC (“Nasdaq”) to delist the common stock of Sangamo Therapeutics, Inc. (the “Company”), the Company’s common stock was suspended from trading on Nasdaq on May 5, 2026 and currently trades on the OTCID Basic Market under the symbol “SGMOQ”. On July 14, 2026, the Nasdaq Hearings Panel issued a written determination letter denying the Company’s request to continue its listing on Nasdaq.

Item 1.03 Bankruptcy or Receivership.

The information set forth under Item 2.01 below is incorporated into this Item 1.03 by reference.

Item 2.01 Completion of Acquisition or Disposition of Assets.

As previously disclosed, on June 23, 2026, Sangamo Therapeutics, Inc. (the “Company”) filed a voluntary petition for relief (Case No. 26-10989) under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the “Court” and such case, the “Chapter 11 Case”). The Company has continued to operate its business as a “debtor-in-possession” under the jurisdiction of the Court and in accordance with the applicable provisions of the Bankruptcy Code.

On July 14, 2026, the Court entered an order approving bidding procedures (the “Bid Procedures Order”) (Docket No. 122), which, among other things, authorized the Company to identify one or more purchasers, subject to the Court’s approval, in connection with the sale of substantially all of the Company’s assets and enter into one or more related purchase agreements. Pursuant to the Bid Procedures Order, the bid deadline was 5:00 p.m. (Eastern Time) on August 4, 2026, and the Company conducted a court-supervised auction process on August 10, 2026, at which Eli Lilly and Company (“Lilly”) was selected as the successful bidder for the Lilly Assets (as defined below).

On August 20, 2026, the Court entered a Sale Order authorizing the sale of the Lilly Assets pursuant to the terms of the Asset Purchase Agreement (as defined below) (Docket No. 362). Accordingly, on September 4, 2026, the Company completed the previously announced sale of its technology platforms, including its AAV capsid engineering platform, including the Company’s proprietary novel capsid known as STAC-BBB and related next-generation variants and related technology; its zinc finger protein technology platform; its Modular Integrase genome editing platform; the Company’s prion disease program (ST-506); certain intellectual property rights relating to the foregoing; and the Company’s rights to receive certain payments on account of certain of its outlicensing agreements, including the right to receive future milestone and royalty payments thereunder (collectively, the “Lilly Assets”), as contemplated by the Asset Purchase Agreement, dated June 22, 2026, by and among the Company, the Company’s wholly-owned subsidiaries, Merope Acquisition Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of Lilly, and Lilly (solely as guarantor for purposes of section 10.21 of the Asset Purchase Agreement) (the “Asset Purchase Agreement”), for \$50 million in cash and the assumption of certain specified liabilities related to the Lilly Assets.

The foregoing summary of the Asset Purchase Agreement and the transactions contemplated thereby is not complete and is qualified in its entirety by reference to the full text of the Asset Purchase Agreement, a copy of which is filed as Exhibit 2.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

On September 2, 2026, the Company filed with the Court its monthly operating report for the period beginning July 1, 2026 and ended July 31, 2026 (the “MOR”).

The information set forth in Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information required to be disclosed solely by Regulation FD. The MOR is attached hereto as Exhibit 99.1. The MOR and additional information regarding the Chapter 11 Case is available at <https://www.veritaglobal.net/SangamoTherapeutics>. The documents and other information on this website are not part of this Current Report on Form 8-K and shall not be incorporated by reference.

The information contained in this Item 7.01 and in Exhibit 99.1 is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

Cautionary Statement Regarding the MOR

The Company cautions investors and potential investors not to place undue reliance upon the information contained in the MOR, which was not prepared for the purpose of providing the basis for an investment decision relating to any of the securities of the Company. The MOR is limited in scope, covers a limited time period and has been prepared solely for the purpose of complying with the reporting requirements of the Court. The MOR is not audited or reviewed by independent accountants, was not prepared in accordance with generally accepted accounting principles in the United States, is in a format prescribed by applicable bankruptcy laws or rules, and is subject to future adjustment and reconciliation. The MOR also contains information for periods shorter and otherwise different from those contained in the Company's reports required to be filed pursuant to the Exchange Act. There can be no assurance that, from the perspective of an investor or potential investor in the Company's securities, the MOR is complete. Results set forth in the MOR should not be viewed as indicative of future results.

Cautionary Language Regarding Trading in the Company's Common Stock

The Company's stockholders are cautioned that trading in the Company's common stock during the pendency of the Chapter 11 Case is highly speculative and poses substantial risks. The Company's common stock has been suspended from trading on, and the Company received a notice of delisting from, the Nasdaq Capital Market and is currently trading on the OTCID Basic Market under the symbol "SGMOQ," and trading prices for the Company's common stock may bear little or no relationship to the actual recovery, if any, by holders thereof in the Company's Chapter 11 Case. Accordingly, the Company urges extreme caution with respect to existing and future investments in its common stock.

Item 9.01. Financial Statements and Exhibits.

(b) Pro Forma Financial Information

The Company is currently unable to prepare pro forma financial information reflecting the transaction described in Item 2.01 of this Current Report without unreasonable effort or expense and thus such information is not reasonably available to the Company within the meaning of Rule 12b-21 under the Securities Exchange Act of 1934, as amended. As a debtor-in-possession under the Bankruptcy Code, the Company files monthly operating reports with the Court, which reports include financial statements that are limited in scope and prepared solely for the purpose of complying with requirements of the Court. The Company cautions investors and potential investors not to place undue reliance upon the information contained in the monthly operating reports, which are not prepared for the purpose of providing the basis for an investment decision relating to any of the securities of the Company.

(d) Exhibits

Exhibit No.	Description
2.1#	Asset Purchase Agreement, dated June 22, 2026, by and among Sangamo Therapeutics, Inc., Merope Acquisition Sub, LLC, Eli Lilly and Company, and Sangamo Therapeutics UK Ltd., Sangamo Therapeutics France SAS, and Ceregene, Inc. (incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K/A filed on June 23, 2026)
99.1	Sangamo Therapeutics, Inc. Monthly Operating Report for the period ended July 31, 2026.
104	Cover Page Interactive Data File (embedded within Inline XBRL document).

Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SANGAMO THERAPEUTICS, INC.

Dated: September 8, 2026

By: /s/ SCOTT B. WILLOUGHBY
Name: Scott B. Willoughby
Title: Chief Legal Officer and Corporate Secretary

UNITED STATES BANKRUPTCY COURT
DISTRICT OF DELAWARE

In Re. SANGAMO THERAPEUTICS, INC.

§
§
§
§

Case No. 26-10989

Debtor(s)

☐ Jointly Administered**Monthly Operating Report**

Chapter 11

Reporting Period Ended: 07/31/2026

Petition Date: 06/23/2026

Months Pending: 1

Industry Classification: 3 2 5 4

Reporting Method:

Accrual Basis ☒Cash Basis ☐

Debtor's Full-Time Employees (current):

73

Debtor's Full-Time Employees (as of date of order for relief):

74

Supporting Documentation (check all that are attached):

(For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor)

- ☒ Statement of cash receipts and disbursements
- ☒ Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit
- ☒ Statement of operations (profit or loss statement)
- ☐ Accounts receivable aging
- ☐ Postpetition liabilities aging
- ☐ Statement of capital assets
- ☐ Schedule of payments to professionals
- ☒ Schedule of payments to insiders
- ☒ All bank statements and bank reconciliations for the reporting period
- ☐ Description of the assets sold or transferred and the terms of the sale or transfer

/s/ Nikunj Jain

Signature of Responsible Party

09/02/2026

Date

Nikunj Jain

Printed Name of Responsible Party

501 Canal Blvd., Suite A100 Richmond, CA 94804
Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, 1320.4(a)(2) applies.



261098926090200000000008

Debtor's Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Part 1: Cash Receipts and Disbursements		Current Month	Cumulative
a.	Cash balance beginning of month	\$14,382,244	
b.	Total receipts (net of transfers between accounts)	\$18,058,990	\$28,562,062
c.	Total disbursements (net of transfers between accounts)	\$15,534,279	\$16,512,210
d.	Cash balance end of month (a+b-c)	\$16,906,955	
e.	Disbursements made by third party for the benefit of the estate	\$0	\$0
f.	Total disbursements for quarterly fee calculation (c+e)	\$15,534,279	\$16,512,210

Part 2: Asset and Liability Status (Not generally applicable to Individual Debtors. See Instructions.)		Current Month
a.	Accounts receivable (total net of allowance)	\$500,160
b.	Accounts receivable over 90 days outstanding (net of allowance)	\$90,355
c.	Inventory (Book ☐ Market ☐ Other ☒ (attach explanation))	\$0
d.	Total current assets	\$20,386,655
e.	Total assets	\$155,117,944
f.	Postpetition payables (excluding taxes)	\$18,768,593
g.	Postpetition payables past due (excluding taxes)	\$366,473
h.	Postpetition taxes payable	\$269,455
i.	Postpetition taxes past due	\$0
j.	Total postpetition debt (f+h)	\$19,038,048
k.	Prepetition secured debt	\$0
l.	Prepetition priority debt	\$32,543
m.	Prepetition unsecured debt	\$78,061,802
n.	Total liabilities (debt) (j+k+l+m)	\$97,132,393
o.	Ending equity/net worth (e-n)	\$57,985,551

Part 3: Assets Sold or Transferred		Current Month	Cumulative
a.	Total cash sales price for assets sold/transferred outside the ordinary course of business	\$0	\$0
b.	Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business	\$0	\$0
c.	Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b)	\$0	\$0

Part 4: Income Statement (Statement of Operations) (Not generally applicable to Individual Debtors. See Instructions.)		Current Month	Cumulative
a.	Gross income/sales (net of returns and allowances)	\$720,000	
b.	Cost of goods sold (inclusive of depreciation, if applicable)	\$0	
c.	Gross profit (a-b)	\$720,000	
d.	Selling expenses	\$0	
e.	General and administrative expenses	\$3,764,872	
f.	Other expenses	\$3,231,570	
g.	Depreciation and/or amortization (not included in 4b)	\$216,290	
h.	Interest	\$105,000	
i.	Taxes (local, state, and federal)	\$0	
j.	Reorganization items	\$4,244,225	
k.	Profit (loss)	\$-11,165,298	\$-14,920,356

Debtor's Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Part 5: Professional Fees and Expenses

a.			Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative
	Debtor's professional fees & expenses (bankruptcy) <i>Aggregate Total</i>					
	<i>Itemized Breakdown by Firm</i>					
	Firm Name	Role				
i						
ii						
iii						
iv						
v						
vi						
vii						
viii						
ix						
x						
xi						
xii						
xiii						
xiv						
xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						
xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						

Debtor's Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						
xliv						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						

Debtor's Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						
xc i						
xc ii						
xc iii						
xc iv						
xc v						
xc vi						
xc vii						
xc viii						
xc ix						
c						
ci						

b.			Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative
	Debtor's professional fees & expenses (nonbankruptcy) <i>Aggregate Total</i>					
	<i>Itemized Breakdown by Firm</i>					
	Firm Name	Role				
i						
ii						
iii						
iv						
v						
vi						
vii						
viii						
ix						
x						
xi						
xii						
xiii						
xiv						

6

Debtor's Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						
xc i						
xcii						
xciii						
xciv						
xcv						
xcvi						
xcvii						
xcviii						

Debtor's Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

c.	xcix						
	c						
All professional fees and expenses (debtor & committees)				\$0	\$0	\$0	\$0

Part 6: Postpetition Taxes		Current Month	Cumulative
a.	Postpetition income taxes accrued (local, state, and federal)	\$0	\$0
b.	Postpetition income taxes paid (local, state, and federal)	\$0	\$0
c.	Postpetition employer payroll taxes accrued	\$226,736	\$282,175
d.	Postpetition employer payroll taxes paid	\$421,834	\$421,834
e.	Postpetition property taxes paid	\$0	\$0
f.	Postpetition other taxes accrued (local, state, and federal)	\$39,582	\$57,404
g.	Postpetition other taxes paid (local, state, and federal)	\$0	\$0

Part 7: Questionnaire - During this reporting period:

- a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes ☒ No ☐
- b. Were any payments made outside the ordinary course of business without court approval? (if yes, see Instructions) Yes ☐ No ☒
- c. Were any payments made to or on behalf of insiders? Yes ☒ No ☐
- d. Are you current on postpetition tax return filings? Yes ☒ No ☐
- e. Are you current on postpetition estimated tax payments? Yes ☒ No ☐
- f. Were all trust fund taxes remitted on a current basis? Yes ☒ No ☐
- g. Was there any postpetition borrowing, other than trade credit? (if yes, see Instructions) Yes ☒ No ☐
- h. Were all payments made to or on behalf of professionals approved by the court? Yes ☐ No ☐ N/A ☒
- i. Do you have:
- Worker's compensation insurance? Yes ☒ No ☐
- If yes, are your premiums current? Yes ☒ No ☐ N/A ☐ (if no, see Instructions)
- Casualty/property insurance? Yes ☒ No ☐
- If yes, are your premiums current? Yes ☒ No ☐ N/A ☐ (if no, see Instructions)
- General liability insurance? Yes ☒ No ☐
- If yes, are your premiums current? Yes ☒ No ☐ N/A ☐ (if no, see Instructions)
- j. Has a plan of reorganization been filed with the court? Yes ☐ No ☒
- k. Has a disclosure statement been filed with the court? Yes ☐ No ☒
- l. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes ☒ No ☐

Debtor's Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Part 8: Individual Chapter 11 Debtors (Only)

- | | |
|--|-----|
| a. Gross income (receipts) from salary and wages | \$0 |
| b. Gross income (receipts) from self-employment | \$0 |
| c. Gross income from all other sources | \$0 |
| d. Total income in the reporting period (a+b+c) | \$0 |
| e. Payroll deductions | \$0 |
| f. Self-employment related expenses | \$0 |
| g. Living expenses | \$0 |
| h. All other expenses | \$0 |
| i. Total expenses in the reporting period (e+f+g+h) | \$0 |
| j. Difference between total income and total expenses (d-i) | \$0 |
| k. List the total amount of all postpetition debts that are past due | \$0 |
| l. Are you required to pay any Domestic Support Obligations as defined by 11 U.S.C § 101(14A)? Yes ☐ No ☒ | |
| m. If yes, have you made all Domestic Support Obligation payments? Yes ☐ No ☐ N/A ☒ | |

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate.

/s/ Nikunj Jain

Signature of Responsible Party

Interim Chief Financial Officer


Title

Nikunj Jain


Printed Name of Responsible Party

09/02/2026


Date




PageOnePartOne



PageOnePartTwo




PageTwoPartOne




PageTwoPartTwo

Debtor's Name SANGAMO THERAPEUTICS, INC.


Case No. 26-10989




Bankruptcy1to50



Bankruptcy51to100




NonBankruptcy1to50




NonBankruptcy51to100

Debtor's Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989



PageThree



Pagefour

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT DELAWARE**

In re:	)	Chapter 11
	)	
SANGAMO THERAPEUTICS, INC.	)	Case No. 26-10989 (CTG)
	)	
Debtor. ¹	)	
	)	

GLOBAL NOTES AND STATEMENT OF LIMITATIONS, METHODOLOGY, AND DISCLAIMERS REGARDING THE DEBTOR'S MONTHLY OPERATING REPORT

On June 23, 2026 (the “**Petition Date**”), Sangamo Therapeutics, Inc. (the “**Debtor**”) commenced the above-captioned chapter 11 case by filing a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the “**Bankruptcy Code**”) with the United States Bankruptcy Court for the District of Delaware (the “**Court**”). The Debtor is authorized to operate its business as a debtor-in-possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code.

General Methodology

The Debtor is filing its monthly operating report (the “**MOR**”) for the period from July 1, 2026 through July 31, 2026 (the “**Reporting Period**”) for purposes of complying with the monthly reporting requirements applicable in the Debtor’s chapter 11 case. The MOR is unaudited and has not been prepared in accordance with accounting principles generally accepted in the United States of America (“**U.S. GAAP**”) and does not include all of the information and footnotes required by U.S. GAAP. The MOR is not intended to reconcile to any financial statements otherwise prepared or distributed by the Debtor. The MOR should not be relied upon by any persons for information relating to current or future financial condition, events, or performance of the Debtor or its affiliates, as the results of operations contained herein are not necessarily indicative of results which may be expected from any other period or for the full year and may not necessarily reflect the results of operations, financial position, and schedule of receipts and disbursements in the future.

Basis for Presentation

In preparing the MOR, the Debtor relied on financial information from its books and records at the time of such preparation. The financial information contained in the MOR is derived from the Debtor's books and records without, among other things, all adjustments or reclassification that may be necessary or typical to accord with U.S. GAAP.

¹ The Debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc. (9556). The Debtor's mailing address is 501 Canal Blvd., Ste A100, Richmond, CA 94804.

This information has not been subjected to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP or any other recognized financial reporting framework. If such procedures were applied, the Debtor believes that the financial information presented in the MOR could be subject to change, including material change.

Although the Debtor made efforts to ensure the accuracy and completeness of the MOR, given the complexity of the Debtor's business, inadvertent errors or omissions may occur. Accordingly, the Debtor hereby reserves all rights to dispute the nature, validity, status, enforceability, or executory nature of any claim amount, agreement, representation, or other statement set forth in the MOR. Further, the Debtor reserves the right to amend or supplement the MOR, if necessary, but shall be under no obligation to do so.

Moreover, given, among other things, the uncertainty surrounding the valuation and ownership of certain assets and the valuation and nature of certain liabilities, to the extent the Debtor shows more assets than liabilities, it is not an admission that the Debtor was solvent as of the Petition Date or at any time prior to the Petition Date. Likewise, to the extent the Debtor shows more liabilities than assets, it is not an admission that the Debtor was insolvent at the Petition Date or any time prior to the Petition Date.

For the reasons discussed above, there can be no assurance that the financial information presented in the MOR is complete, and readers are strongly cautioned not to place undue reliance on the MOR.

Each signatory to the MOR has necessarily relied upon the efforts, statements, advice, and representations of personnel of the Debtor and the Debtor's advisors and professionals. Each signatory has not (and could not have) personally verified the accuracy of each such statement, representation, and answer contained in the MOR.

Reporting Period

Unless otherwise noted herein, the MOR generally reflects the Debtor's books and records for the applicable Reporting Period. Unless otherwise noted herein, no adjustments have been made for activity occurring after the close of the Reporting Period.

Accuracy

The financial information disclosed in the MOR was not prepared in accordance with federal or state securities laws or other applicable non-bankruptcy law or in lieu of complying with any periodic reporting requirements thereunder. Persons and entities trading in or otherwise purchasing, selling, or transferring the claims against or equity interests in the Debtor should evaluate the financial information in light of the purposes for which it was prepared. The Debtor and its advisors are not liable for and undertake no responsibility to indicate variations from securities laws in the MOR or for any evaluations of the Debtor, including of their financial condition, based on this financial information or any other information.

Debtor in Possession Financing

On June 25, 2026, the Court entered the *Interim Order (A) Authorizing the Debtor to Obtain Postpetition Financing, (B) Granting Liens and Providing Claims with Superpriority*

Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief [Docket No. 63] (the “**Initial Interim DIP Order**”) authorizing the Debtor to enter into a senior secured superpriority debtor-in-possession term loan facility (the “**Initial DIP Facility**”). Prior to the Reporting Period, the Debtor drew \$10,500,000 under the Initial DIP Facility. Please refer to the motion [Docket No. 10] seeking entry of the Initial Interim DIP Order for additional information regarding the Initial DIP Facility.

On July 23, 2026, the Court entered the *Interim Order (A) Authorizing the Debtor to Obtain Replacement Postpetition Financing, (B) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief* [Docket No. 176] (the “**Replacement Interim DIP Order**”), which among other things, authorized the Debtor to enter into a senior secured superpriority debtor-in-possession term loan facility (the “**Replacement DIP Facility**”) to replace the Initial DIP Facility. During the Reporting Period, the Debtor incurred \$18 million in DIP Obligations (as defined in the Replacement DIP Order) under the Replacement DIP Order, \$11,432,958 of which was paid by the Debtor or on the Debtor’s behalf to satisfy all outstanding obligations arising under the Initial DIP Facility, including all fees. Please refer to the motion [Docket No. 161] seeking entry of the Replacement Interim DIP Order for additional information regarding the Replacement DIP Facility.

Payment of Prepetition Claims Pursuant to First Day Orders

Pursuant to certain interim orders of the Court entered on or about June 24, 2026 and final orders of the Court entered on or about July 21, 2026 (the “**First Day Orders**”), the Debtor is authorized (but not directed) to pay, among other things, certain prepetition claims of employees and taxing authorities. Accordingly, these liabilities may have been or may be satisfied in accordance with such First Day Orders. To the extent any payments were made on account of prepetition claims following the Petition Date pursuant to the authority granted to the Debtor under the First Day Orders, such payments have been included in the MOR (subject to the notes and statements and limitations provided herein).

Reservation of Rights

The Debtor reserves all rights to amend or supplement the MOR in all respects, as may be necessary or appropriate. Nothing contained in the MOR shall constitute a waiver of any of the Debtor’s rights or an admission with respect to any claim against the Debtor or otherwise in connection with this chapter 11 case.

Specific MOR Disclosures

Part 1: Cash Receipts and Disbursements

Pursuant to the Initial Interim DIP Order and Replacement Interim DIP Order (together the “**Interim DIP Orders**”), fees and expenses of estate professionals were placed into the Professional Fees Account (as defined in the Interim DIP Orders) maintained by the Debtor. The transfer of such funds to the Professional Fee Account were treated as a transfer between Debtor accounts, and, therefore, were not treated as a distribution in Part 1(c). Professional fees will be

treated as a disbursement in the reporting period in which they are paid to the applicable professionals.

Similarly, pursuant to the interim and final orders approving, among other things, the Debtor's proposed form of adequate assurance of payment to utility companies [Docket No. 56 & 142] (the "Utilities Orders"), the Debtor deposited funds into the Utility Deposit Account (as defined in the Utilities Orders) maintained by the Debtor prior to the Reporting Period. The funds in such account will be treated as disbursements only if they are ultimately paid to a third party.

Notes to Part 2: Asset and Liability Status

Unless otherwise noted, all asset and liability information included in the MOR reflects net book value, which may differ from current market value. As set forth above, this information has not been subjected to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP or any other recognized financial reporting framework. If such procedures were applied, the Debtor believes that the financial information presented in the MOR could be subject to change, including material change. Asset and liability information includes intercompany claims and other assets and liabilities which may not be settled in cash.

The Debtor continues to pay postpetition invoices on account of postpetition goods provided and services rendered in the ordinary course of business.

Given the Petition Date did not occur at month end, certain prepetition and postpetition liability balances are estimated. The Debtor has sought to assign liabilities to the prepetition and postpetition periods based on the information available as of and at the time the MOR was prepared. As additional information becomes available, the allocation of liabilities between prepetition and postpetition periods may change. The Debtor reserves the right to amend the balances as it deems appropriate and any such amendments will be reflected in future MORs

The amounts listed as "Prepetition Secured Debt," "Prepetition Priority Debt" and "Prepetition Unsecured Debt" are preliminary and are subject to ongoing review and reconciliation by the Debtor. All amounts and classifications are subject to material adjustments.

Regarding Part 2c, the Debtor does not hold inventory; therefore, no inventory valuation method is applicable.

Notes to Part 6: Postpetition Taxes

Regarding Part 6c and 6d, postpetition employer payroll taxes accrued and paid include both the employer and employee portions of payroll taxes.

Notes to Part 7: Questionnaire

Regarding Part 7a, and as mentioned above, the Debtor is authorized to pay certain prepetition claims and obligations pursuant to the First Day Orders.

Regarding Part 7g, the Debtor incurred \$18 million in DIP Obligations under the Replacement DIP Facility during the Reporting Period. The DIP Obligations were paid by the Debtor or on the

Debtor's behalf to pay all outstanding obligations under the Initial DIP Facility and to fund the Debtor's business operations and its chapter 11 case.

RLF1 36431088v.1

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.

Case No: 26-10989

Schedule of Post-Petition Borrowing Activity

Reporting Period: July 1, 2026 – July 31, 2026

The Debtor hereby submits this attestation regarding postpetition borrowing during the period of July 1, 2026 through July 31, 2026.

In accordance with the *Interim Order (A) Authorizing the Debtor to Obtain Replacement Postpetition Financing, (B) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief* [Docket No. 176] (the “**Replacement Interim DIP Order**”), the Debtor incurred \$18 million in DIP Obligations under the Replacement DIP Facility (each as defined in the Replacement Interim DIP Order) during the Reporting Period.

/s/ Nikunj Jain

Signature of Authorized Individual

Nikunj Jain

Printed Name of Authorized Individual

September 2, 2026

Date

Interim Chief Financial Officer

Title of Authorized Individual

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.

Case No: 26-10989

Schedule of Payments on Prepetition Debt

Reporting Period: July 1, 2026 – July 31, 2026

All payments made by the Debtor during the Reporting Period (and included in the disbursements reported in this MOR) were authorized under various final orders granted by the Court, which authorized the Debtor's various motions that were filed following the commencement of the chapter 11 case.

/s/ Nikunj Jain

Signature of Authorized Individual

Nikunj Jain

Printed Name of Authorized Individual

September 2, 2026

Date

Interim Chief Financial Officer

Title of Authorized Individual

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.
Schedule of Payments to Insiders

Case No: 26-10989
Reporting Period: July 1, 2026 – July 31, 2026

The Debtor hereby submits this attestation regarding payments to insiders during the period of July 1, 2026 through July 31, 2026.

With respect to insiders, all cash payments made were on account of ordinary course salaries and authorized travel and expense reimbursements.

No non-cash transfers were made during this reporting period.

/s/ Nikunj Jain

Signature of Authorized Individual

Nikunj Jain

Printed Name of Authorized Individual

September 2, 2026

Date

Interim Chief Financial Officer

Title of Authorized Individual

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.
All bank statements and bank
reconciliations for the reporting period

Case No: 26-10989
Reporting Period: July 1, 2026 – July 31, 2026

The Debtor hereby submits this attestation regarding bank account reconciliations in lieu of providing copies of bank statements, bank reconciliations, and journal entries.

The Debtor's standard practice is to ensure that bank reconciliations are completed as part of the month end close each reporting period. I attest that each of the Debtor's bank accounts has been reconciled in accordance with their standard practices.

/s/ Nikunj Jain

Signature of Authorized Individual

Nikunj Jain

Printed Name of Authorized Individual

September 2, 2026

Date

Interim Chief Financial Officer

Title of Authorized Individual

Sangamo Therapeutics Inc.*MOR #2 - Statement of cash receipts and disbursements**Units (i.e. \$ in 000s)*07/01/2026 -
07/31/2026**Receipts**

Receipts	\$59
DIP Draw	\$18,000
Total Receipts	\$18,059

Operational Disbursements

Payroll & Benefits	\$1,747
Rent & Facilities	1,348
Program Costs	319
International Operations	416
Other Operating Disbursements	271
Total Operational Disbursements	\$4,101

Restructuring Disbursements

Professional Fees	-
US Trustee Fees	-
DIP Interest & Fees	933
DIP Repayments	10,500
Total Restructuring Disbursements	\$11,433

Net Cash Flow**\$2,525**

Cash, cash equivalents, and restricted cash, beginning of period \$14,382

Cash, cash equivalents, and restricted cash, end of period \$16,907

Sangamo Therapeutics Inc.*MOR #2 - Balance sheet**Units (i.e. \$ in 000s)*

	As of	
	6/30/2026	7/31/2026
Assets		
Cash, Cash Equivalents and Restricted Cash	\$14,382	\$16,910
Accounts Receivables	500	500
Other Current Assets	3,303	2,977
Inventory	-	-
I/C Receivables - Current	-	-
Total Current Assets	\$18,186	\$20,387
Property, Plant & Equipment (Net)	\$9,644	\$9,430
Right of Use Assets	2,747	2,694
Other Non-Current Assets	779	779
Investments in Subsidiaries	115,762	115,762
I/C Receivables - Non-Current	5,970	6,067
Total Non-Current Assets	\$134,902	\$134,731
Total Assets	\$153,087	\$155,118
Liabilities and Stockholders' Equity		
A/P and Accrued Liabilities	\$30,620	\$36,735
Compensation and Benefits Liabilities	13,304	17,304
DIP Loan Payables	10,500	18,000
Other Current Liabilities ¹	9,001	8,713
I/C Payables - Current	42,651	42,687
Other Non-Current Liabilities ¹	23,678	23,240
I/C Payables - Non-Current	692	703
Non-Current Portion of Long-Term Debt	-	-
Total Liabilities	\$130,446	\$147,383
Stock	\$1,643,342	\$1,643,342
Retained Earnings	(1,564,836)	(1,564,836)
Other Equity	(30)	(30)
Net Income	(55,834)	(70,741)
Total Stockholders' Equity	\$22,642	\$7,735
Total Liabilities and Stockholders' Equity	\$153,087	\$155,118

Notes:¹ Includes Deferred Revenues and Lease Liabilities

Sangamo Therapeutics Inc.*MOR #2 - Statement of operations (profit or loss statement)**Units (i.e. \$ in 000s)*07/01/2026 -
07/31/2026

Total Revenue	\$720
COGS	-
Gross Profit	\$720
Personnel & Staffing Costs ¹	\$1,931
R&D Expenses ²	3,184
Selling Expenses	-
General and Administrative Expenses	863
Facilities & OH Expenses ¹	972
I/C Expenses ²	28
Other Expenses ²	19
Interest Expense	105
Restructuring Expenses ³	4,244
Depreciation and/or amortization	216
Total Operating Expenses	\$11,562
Unrealized FX (Gain)/Loss	\$336
Non-Operating (Income)/Expense	(12)
Total Non-Operating (Income)/Expense	\$323
Net Profit/(Loss) for the Period	(\$11,165)

Notes:

1 Considered under "General and Administrative Expenses" for MOR

2 Considered under "Other Expenses" for MOR

3 Includes professional fees and DIP loan fees accruals

Sangamo Therapeutics Inc.

*MOR #2 - Detailed explanations***Part 2 - Question C - Inventory**

Sangamo does not hold inventory; therefore, no inventory valuation method is applicable

Part 7 - Question G - Was there any postpetition borrowing, other than trade credit?

Detail	Date	Payee/Lender Name	Amount
DIP Replacement - Future Solutions Invenstment	7/24/2026	Future Solution Investments LLC	\$18,000,000